We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Mammoth Biosciences Presents AACC 2021 Disruptive Technology Award Finalist CRISPR-Based Detection Platform

By LabMedica International staff writers
Posted on 29 Sep 2021

Illustration

Mammoth Biosciences (San Francisco, CA, USA) presented its revolutionary CRISPR-based detection platform that is enabling limitless testing possibilities and was also one of the AACC 2021 Disruptive Technology award finalists.

Mammoth has catalyzed a new approach to molecular diagnostics, called DETECTR. Based on CRISPR, this programmable platform acts as a search engine for biology and is capable of finding and identifying any nucleic acid sequence in the genome. Using proprietary technology licensed exclusively from the University of California, Berkeley and developed internally, Mammoth is working on multiple form factors and test targets from infectious diseases to cancer. For example, DETECTR was configured in less than two weeks to detect SARS-CoV-2, demonstrating the platform’s ability to be quickly tailored to identify any DNA or RNA target. The resulting product, DETECTR BOOST, is a reagent kit that when combined with standard laboratory automation provides labs with unparalleled high throughput molecular testing.

Mammoth was also one of the AACC 2021 Disruptive Technology award finalists. AACC's Disruptive Technology Award Competition recognizes innovative testing and disruptive technology solutions that improve patient care through diagnostic performance or access to high quality testing. It provides an opportunity for early to mid-stage start-ups in the medical device, diagnostic, or digital health/health IT spaces to showcase their technology and present to a large audience and a panel of judges.

Related Links:
Mammoth Biosciences

Visit expo >

Gold Member

Automated MALDI-TOF MS System

EXS 3000

POC Helicobacter Pylori Test Kit
Hepy Urease Test

Automated Chemiluminescence Immunoassay Analyzer

MS-i3080

Alcohol Testing Device

Dräger Alcotest 7000

ADLM

Latest AACC 2021 News

Channels

Clinical Chemistry

view channel

Image: The ARi-FL fluorescent probe offers a clearer view of tumor behavior and treatment resistance (J. Med. Chem. 2025, 68, 15, 15812-15827)

Chemical Imaging Probe Could Track and Treat Prostate Cancer

Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more

Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems

Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read more

Image: Schematic diagram of esophageal cancer cell identification research process (Photo courtesy of GE Dianlong)

VOCs Show Promise for Early Multi-Cancer Detection

Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. This makes it difficult to identify... Read more

Image: Portable Raman spectroscopy could help detect kidney disease at POC (Photo courtesy of Shutterstock)

Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC

Kidney disease is typically diagnosed through blood or urine tests, often when patients present with symptoms such as blood in urine, shortness of breath, or weight loss. While these tests are common,... Read more

Molecular Diagnostics

view channel

Image: The newly discovered cells explain why some children with acute lymphoblastic leukemia do not respond well to treatment (Photo courtesy of Shutterstock)

Genetic Marker to Help Children with T-Cell Leukemia Avoid Unnecessary Chemotherapy

About 400 children in the UK are diagnosed with acute lymphoblastic leukemia (ALL) each year, with roughly 15% presenting with a more aggressive T-ALL subtype. While the standard approach is a four-week... Read more

Image: A minimal four-gene host-response signature detected in blood can exclude bacterial respiratory infections (Photo courtesy of 123RF)

Four-Gene Blood Test Rules Out Bacterial Lung Infection

Lower respiratory tract infections (LRTIs) are among the most common reasons for antibiotic prescriptions, yet distinguishing bacterial infections from viral ones remains notoriously difficult.... Read more

New PCR Test Improves Diagnostic Accuracy of Bacterial Vaginosis and Candida Vaginitis

Bacterial vaginosis (BV) impacts approximately 25% of women of reproductive age, while up to 75% of women experience candida vaginitis (CV) at least once in their lifetime. Vaginal symptoms are one of... Read more

New Serum Marker-Editing Strategy to Improve Diagnosis of Neurological Diseases

Tracking gene-expression changes in the brain is crucial for understanding neurological diseases, yet current monitoring tools are invasive or unable to capture subtle activity shifts over time.... Read more

Hematology

view channel

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more

Image: Sickle cell disease patients with higher levels of RMVs, AMVs, and EMVs were found to have more severe disease (Photo courtesy of Adobe Stock)

Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients

Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more

ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners

Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel

New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection

Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more

Gene Signature Test Predicts Response to Key Breast Cancer Treatment

DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more

Image: The labyrinth chip could one day help doctors look for aggressive, stem-like cancer cells in patient blood (Photo courtesy of Joseph Xu/Michigan Engineering)

Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment

Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read more

Image: The new liquid biopsy model can predict patient response to immune checkpoint therapies (Photo courtesy of 123RF)

Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness

Immunotherapy has revolutionized cancer care by harnessing the immune system to fight tumors, yet predicting who will benefit remains a major challenge. Many patients undergo costly and taxing treatment... Read more

Microbiology

view channel

Image: The rapid sepsis test detected nearly three times more bloodstream infections than conventional blood cultures (Photo courtesy of Adobe Stock)

Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection

Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read more

Rapid POC Tuberculosis Test Provides Results Within 15 Minutes

Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more

Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples

Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read more

Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis

Extrapulmonary tuberculosis (EPTB) remains difficult to diagnose and treat because it spreads beyond the lungs and lacks easily accessible biomarkers. Despite TB infecting 10 million people yearly, the... Read more

Pathology

view channel

AI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities

Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read more

Image: SMMILe enables accurate spatial quantification in digital pathology using multiple-instance learning (Gao, Z et al. Nature Cancer, 2025; DOI: 10.1038/s43018-025-01060-8)

AI Tool Rapidly Analyzes Complex Cancer Images for Personalized Treatment

Complex digital biopsy images that typically take an expert pathologist up to 20 minutes to assess can now be analyzed in about one minute using a new artificial intelligence (AI) tool. The technology... Read more

Diagnostic Technology Performs Rapid Biofluid Analysis Using Single Droplet

Diagnosing disease typically requires milliliters of blood drawn at clinics, depending on needles, laboratory infrastructure, and trained personnel. This process is often painful, resource-intensive, and... Read more

Novel Technology Tracks Hidden Cancer Cells Faster

Targeting and treating disease often hinges on the ability to locate specific cells inside the body—a challenge made difficult because harmful or therapeutic cells move through tissues and are not easily detected.... Read more

Technology

view channel

Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis

Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more

Image: The technology can diagnose head and neck cancer early with a drop of saliva (Photo courtesy of Adobe Stock)

AI Saliva Sensor Enables Early Detection of Head and Neck Cancer

Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more

Image: The screen-printed electrochemical sensor (Photo courtesy of UT Dallas)

AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection

Detecting lung cancer early remains one of the biggest challenges in oncology, largely because current tools are invasive, expensive, or unable to identify the disease in its earliest phases.... Read more

AI Model Achieves Breakthrough Accuracy in Ovarian Cancer Detection

Early diagnosis of ovarian cancer remains one of the toughest challenges in women’s health. Traditional tools such as the Risk of Ovarian Malignancy Algorithm (ROMA) can struggle to distinguish between... Read more

Industry

view channel

Abbott Acquires Cancer-Screening Company Exact Sciences

Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more

$Image: Freenome will evaluate Roche\'s forthcoming SBX technology for future development applications (Photo courtesy of Roche)$

Roche and Freenome Collaborate to Develop Cancer Screening Tests

Roche (Basel, Switzerland) and Freenome (Brisbane, CA, USA have entered into a strategic collaboration to commercialize Freenome's cancer screening technology in international markets.... Read more

Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) has formed a new artificial intelligence (AI) business unit to integrate the company's existing and planned AI applications into its Co-Dx Primer Ai platform.... Read more

Qiagen Acquires Single-Cell Omics Firm Parse Biosciences

QIAGEN (Venlo, Netherlands) has entered into a definitive agreement to fully acquire Parse Biosciences (Seattle, WA, USA), a provider of scalable, instrument-free solutions for single-cell research.... Read more